Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Award

Photo Pending

Daniel Zwilling, Ph.D.

J. David Gladstone Institutes
San Francisco, CA

Title: The Role of the Kynurenine Pathway in Microglia in Alzheimer's Disease
Non-Technical Title: How immune cells of the brain contribute to Alzheimer's disease

Mentor:
Paul Muchowski, Ph.D.
J. David Gladstone Institutes

Duration: April 1, 2008 - March 31, 2010
Award Type: Research Fellowship
Award Amount: $100,000


Summary:

The major goal of this proposal is to use genetic and pharmacological approaches in mouse models of Alzheimer's disease to characterize the contribution of the microglial kynureine pathway to the pathogenesis of AD which may potentially contribute to the current understanding of pathogenesis of AD and provide new treatments.

Details:

Microglia are specialized brain cells that support the health and function of neurons. In response to brain injuries, these cells produce a large number of molecules that participate in inflammation and wound repair. While acute glial responses may help prevent neuronal damage, prolonged or aberrant activation of these cells may contribute to neurological disease. I am using genetic and pharmacological strategies to assess whether glial cells and their products contribute to cerebral amyloidosis and neurodegeneration in Alzheimer's disease. Researchers have previously found that a certain microglial enzyme that is active in the metabolism of tryptophane (an amino acid) might be responsible for the production of neurotoxic substances. In AD patients this enzyme might be more active than usual. However, the inactivation of this enzyme by drugs might help to prevent the progression of AD pathology. The proposed experiments will increase our understanding of the role of microglia in Alzheimer's disease and may also provide information critical for the preclinical development of drugs for Alzheimer's disease.